Edition:
United States

Aviragen Therapeutics Inc (AVIR.OQ)

AVIR.OQ on NASDAQ Stock Exchange Capital Market

0.59USD
15 Dec 2017
Change (% chg)

$-0.00 (-0.10%)
Prev Close
$0.59
Open
$0.59
Day's High
$0.60
Day's Low
$0.59
Volume
19,379
Avg. Vol
96,327
52-wk High
$1.48
52-wk Low
$0.44

Select another date:

Wed, Nov 29 2017

BRIEF-Aviragen Therapeutics Completes Patient Enrollment In Phase 2 Clinical Trial For Condyloma Treatment

* AVIRAGEN THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TESLEXIVIR (BTA074) FOR THE TREATMENT OF CONDYLOMA

BRIEF-SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics is superior to Vaxart's proposed transaction

* SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics Inc is superior to Vaxart Inc's proposed transaction - SEC Filing

BRIEF-Aviragen Therapeutics Q1 loss per share $0.14

* Aviragen Therapeutics reports first quarter of fiscal year 2018 financial results

BRIEF-Aviragen Therapeutics to pay Vaxart $1.95 mln, if deal terminated

* On termination of merger under specified circumstances, co required to pay Vaxart termination fee of $1.95 million ​- SEC filing

BRIEF-Aviragen Therapeutics and Vaxart enter into merger agreement

* Aviragen Therapeutics and Vaxart enter into merger agreement

BRIEF-Aviragen Therapeutics reports Q4 loss per share $0.15

* Aviragen therapeutics reports fourth quarter and fiscal year 2017 financial results

BRIEF-SC Fundamental Value Fund LP reports 5.01 pct stake in Aviragen Therapeutics Inc as of June 21

* SC Fundamental Value Fund Lp reports 5.01 percent stake in Aviragen Therapeutics Inc as of June 21 - SEC filing Source text - (http://bit.ly/2tsaxus) Further company coverage:

Select another date: